Contineum Therapeutics, Inc. - 8-K Filing

Contineum Therapeutics reports Q3 2026 net loss of $18.7 million and maintains cash runway through mid-2029. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CTNM

Read the full article at SEC EDGAR

More Regulatory news